Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study

Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

Suzanne Mandala, Richard Hajdu, James D. Bergstrom et al. · Science · 2002 · 1.7K citations

Life Sciences, Immunology, Pharmacology +17

EDMUS, a European database for multiple sclerosis.

Christian Confavreux, D. A. S. Compston, O.R. Hommes et al. · Journal of Neurology Neurosurgery & Psychiatry · 1992 · 305 citations · Full text

Health Professions, Biomedical Informatics, Neurology +16

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Peter Alping, Thomas Frisell, Lenka Novakova et al. · Annals of Neurology · 2016 · 229 citations

Life Sciences, Neurology, Pharmacotherapy +16

Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study

Mark C. Genovese, Jeffrey Kaine, Mitchell B. Lowenstein et al. · Arthritis & Rheumatism · 2008 · 205 citations

Medicine, Pharmacology, Pharmacotherapy +16

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

Mikaël Cohen, Élisabeth Maillart, Ayman Tourbah et al. · JAMA Neurology · 2014 · 140 citations

Medicine, Neurology, Pharmacotherapy +16